NVP Healthcare, a leading biohealth company based in South Korea, is on the brink of securing a European patent for its groundbreaking probiotic blend. This innovative complex, aiming to enhance both gut and liver health, holds promise for global expansion following its successful patenting in multiple countries, including Japan, China, the US, and others.
The patent revolves around two key strains of lactic acid bacteria: Lactobacillus plantarum LC27 (L. plantarum LC27) and Bifidobacterium longum LC67 (B. longum LC67). These strains have demonstrated effectiveness in preventing and treating liver ailments such as hepatitis, fatty liver, and cirrhosis.
Utilizing its advanced DuoBiome technology, NVP Healthcare developed NVP-1702, a complex probiotic blend comprising B. longum LC67 sourced from the healthy intestines of Koreans and L. plantarum LC27 from kimchi. This proprietary blend received approval from Korea’s Ministry of Food and Drug Safety (MFDS) as a functional ingredient, marking a significant milestone as the first probiotic recognized for its dual benefits to gut and liver functions.
Clinical trials have further validated the efficacy of NVP-1702, particularly in improving liver damage caused by alcohol consumption. Fatty liver, a prevalent consequence of various factors including obesity and excessive drinking, has been increasingly linked to imbalances in intestinal microbes.
Studies conducted by NVP Healthcare have shown notable improvements in liver damage indicators such as alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transpeptidase (γ-GTP) levels among individuals using NVP-1702. Additionally, reductions in lipopolysaccharides (LPS) levels, which are implicated in liver damage, were observed in both blood and fecal samples, indicating a distinct mechanism of action compared to conventional treatments.
NVP-1702’s ability to mitigate liver damage through inflammation suppression, without burdening the liver with additional synthetic drugs or functional foods, underscores the emerging trend of microbiome-based gut-liver axis control in liver disease management.
In November 2023, NVP Healthcare introduced “Liver lactic acid bacteria NVP-1702,” a health functional food under its Bicrome probiotics brand. This product, available online, represents the culmination of over a decade of research and is poised to redefine the health functional foods market by addressing the growing prevalence of non-alcoholic fatty liver disease (NAFLD).
With NAFLD affecting a significant portion of the population, especially individuals struggling with weight issues or hormonal changes such as menopause, the demand for effective solutions like NVP-1702 continues to escalate. NVP Healthcare envisions its product leading a new era in liver health enhancement, offering hope to millions seeking a natural and sustainable approach to liver wellness.
